Takeda completes seven-year Phase 3 TIDES trial of Qdenga

Takeda (TAK) announced the completion of the seven-year Phase 3 TIDES trial evaluating its dengue vaccine, Qdenga. These data, including an exploratory analysis of a booster dose, confirm the benefit and risk profile of Qdenga and that the two-dose regimen provides sustained protection against dengue. This is consistent with its approved indications in multiple countries worldwide, which could simplify vaccination schedules and increase adherence. After 4.5 years, two doses of Qdenga provided 61.2% vaccine efficacy in preventing virologically confirmed dengue. A booster dose administered at 4.5 years only marginally increased efficacy to 74.3% after two years. Qdenga showed 84.1% VE in preventing dengue-related hospitalizations at 4.5 years, and VE remained consistently high at 90.6% after the booster dose. Overall efficacy was seen across all four dengue virus serotypes through seven years. No new safety signals were observed following the administration of a booster dose.